Hepatoma Research最新文献_第8页

Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant 了解肝移植后HCC使用检查点免疫治疗的免疫学观点和选择

Hepatoma Research Pub Date : 2022-02-11 DOI: 10.20517/2394-5079.2021.123

Chimaobi Anugwom, T. Leventhal, J. Debes

引用次数: 3

Hepatocellular carcinoma on the background of nonalcoholic fatty liver disease: epidemiological update 非酒精性脂肪性肝病背景下的肝细胞癌:流行病学最新进展

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2021.136

Elvire Desjonqueres, E. Gigante

引用次数: 0

Cancer stem cell-mediated therapeutic resistance in hepatocellular carcinoma 肝癌干细胞介导的治疗耐药

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2022.43

Mei-Mei Li, Yi He, Jie-Kai Liang, X. Guan, N. Ma, Ming Liu

引用次数: 2

Old-fashioned and newly discovered biomarkers: the future of NAFLD-related HCC screening and monitoring 老式和新发现的生物标志物:nafld相关HCC筛查和监测的未来

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2022.46

R. Piciotti, M. Longo, Adele Agresta, E. Paolini, A. Cespiati, M. Meroni, P. Dongiovanni

{"title":"Old-fashioned and newly discovered biomarkers: the future of NAFLD-related HCC screening and monitoring","authors":"R. Piciotti, M. Longo, Adele Agresta, E. Paolini, A. Cespiati, M. Meroni, P. Dongiovanni","doi":"10.20517/2394-5079.2022.46","DOIUrl":"https://doi.org/10.20517/2394-5079.2022.46","url":null,"abstract":"Nonalcoholic fatty liver disease (NAFLD) is the major contributor to the global burden of chronic liver diseases and ranges from simple and reversible steatosis to nonalcoholic steatohepatitis (NASH), which may progress into cirrhosis and hepatocellular carcinoma (HCC). HCC represents the most common liver cancer, and it is a leading cause of death worldwide with an increasing trend for the future. Due to late diagnosis, non-responsiveness to systemic therapy, and high cancer heterogeneity, the treatment of this malignancy is challenging. To date, liver biopsy and ultrasound (US) are the gold standard procedures for HCC diagnosis and surveillance, although they are not suitable for mass screening. Therefore, it is impelling to find new, less invasive diagnostic strategies able to detect HCC at an early stage as well as monitor tumor progression and recurrence. Common and rare inherited variations that boost the switching from NASH to liver cancer may help to predict tumor onset. Furthermore, epigenetic changes which reflect intertumoral heterogeneity occur early in tumorigenesis and are highly stable under pathologic conditions. The severity of hepatic injuries can be detected through the analysis of cell circulating tumor DNAs (ctDNAs), microRNAs (miRNAs), and noncoding RNAs (ncRNAs), which are involved in several pathological processes that feature cancer, including cell growth, survival, and differentiation, thus representing appealing biomarkers for HCC. Therefore, this review discusses the current options for HCC surveillance, focusing on the role of genetic and epigenetic biomarkers as new strategies to refine HCC management.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67653706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Liver cancer understaging in liver transplantation in the current era of radiologic imaging and newer generation locoregional therapies 在当前的放射影像时代和新一代的局部治疗中，肝移植中肝癌分期不足

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2021.139

Hannah Lee, D. McClish, Binu V. John, Sarah Winks, Ryan D Clayton, S. Albhaisi, Allawy Allawy, S. Patel, E. Fields, S. Matherly, B. Strife, C. Bhati, Amit Sharma, R. Sterling

{"title":"Liver cancer understaging in liver transplantation in the current era of radiologic imaging and newer generation locoregional therapies","authors":"Hannah Lee, D. McClish, Binu V. John, Sarah Winks, Ryan D Clayton, S. Albhaisi, Allawy Allawy, S. Patel, E. Fields, S. Matherly, B. Strife, C. Bhati, Amit Sharma, R. Sterling","doi":"10.20517/2394-5079.2021.139","DOIUrl":"https://doi.org/10.20517/2394-5079.2021.139","url":null,"abstract":"Background: Discordance in hepatocellular carcinoma (HCC) staging between pre-transplant imaging and explant pathology is associated with an increased risk of recurrence and death. Our aim was to evaluate variables that predicted concordance/discordance in the era of new generation locoregional therapies (LRT) and improved radiologic technology in diagnosis. Methods: A single-center retrospective study was performed on patients who received a liver transplant for HCC between 2008-2019. Pre- and post-LT variables, including type of LRT, downstaging (DS), transplant time period, and radiologic response to LRT, were analyzed for concordance/discordance. Kaplan-Meier analysis was used to assess post-LT survival. Results: Of 146 patients transplanted within Milan Criteria (MC), discordance rates (understaged) were 45%. Discordance was associated with ≥ 3 HCC lesions at diagnosis but not newer generation LRT (transarterial radioembolization/ stereotactic body radiation therapy), traditional LRT or combination. No differences in discordance were seen between transplant periods (2008-2013 vs. 2014-2019), but those within MC in the earlier period had higher concordance rates. A trend was observed between DS and discordance. Conclusion: HCC stage discordance remains common and poorly predictable. Discordance was associated with three or more HCC lesions at the time of diagnosis. Patients within MC transplanted between 2008-2013 was associated with concordance, while a trend was noted between DS and discordance. No other pre- or post- LT variables predicted discordance/ concordance. Discordance was associated with decreased survival.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67653817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Repeat laparoscopic anatomical liver resection in a hepatocellular carcinoma patient: a case report 重复腹腔镜解剖性肝切除术1例肝细胞癌患者报告

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2022.02

K. Igarashi, K. Mishima, T. Ozaki, G. Wakabayashi

引用次数: 0

The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 影响肝细胞癌常规化疗栓塞时间的因素

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2022.18

M. Renzulli, M. Gentilini, G. Marasco, N. Brandi, A. Granito, S. Lo Monaco, A. Ierardi, A. De Cinque, F. Tovoli, L. Bartalena, Daniele Spinelli, F. Piscaglia, R. Golfieri

{"title":"The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time","authors":"M. Renzulli, M. Gentilini, G. Marasco, N. Brandi, A. Granito, S. Lo Monaco, A. Ierardi, A. De Cinque, F. Tovoli, L. Bartalena, Daniele Spinelli, F. Piscaglia, R. Golfieri","doi":"10.20517/2394-5079.2022.18","DOIUrl":"https://doi.org/10.20517/2394-5079.2022.18","url":null,"abstract":"Aim: The present study evaluated the duration of chemoembolization in patients with hepatocellular carcinoma, analyzing possible factors affecting the procedural time. Methods: In total, 175 patients who underwent chemoembolization have been prospectively enrolled. The procedural length was considered the time between the insertion and the removal of the angiographic sheath. The features related to the tumor burden and angiographic procedures, which could be related to the procedural time, were recorded. Results: The chemoembolization time resulted in a mean of 58.1 min. The longer procedural time was associated with a number of nodules treated per patient ≥ 2 (P < 0.001), a number of segments with nodules ≥ 2 (P < 0.001), the presence of more than 1 nodule in the same segment (P < 0.001), the location of the tumor in the left lobe (P = 0.001), the exclusion from the Milan criteria (P < 0.001), and a number of segments treated ≥ 2 (P < 0.001). Only the number of nodules treated per patient resulted significantly in multivariate analysis (OR 2.927, 95%CI: 2.015-4.251, P < 0.001). Conclusion: The factors related to longer procedural time are the number of nodules treated ≥ 2, the number of segments with nodules ≥ 2, the involvement of the left lobe, the tumor burden outside the Milan criteria, and the number of segments treated ≥ 2. All these characteristics, known in the pre-procedural phase, represent useful tools for a correct planning of the angiographic room’s workflow during the pandemic era as well as in the future to reduce downtime and increase productivity.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67653988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Experience of living donor liver transplantation for hepatocellular carcinoma in the University of Hong Kong Hospital 香港大学医院活体肝移植治疗肝癌的经验

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2021.125

J. Mok

{"title":"Experience of living donor liver transplantation for hepatocellular carcinoma in the University of Hong Kong Hospital","authors":"J. Mok","doi":"10.20517/2394-5079.2021.125","DOIUrl":"https://doi.org/10.20517/2394-5079.2021.125","url":null,"abstract":"Aim: To describe the current practise of living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC), including the patient selection criteria, surgical techniques, management of small-for-size syndrome, postoperative complications, and the results of our units, in the Liver Transplant Centre of Queen Mary Hospital, Hong Kong, one of the high-volume centres for LDLT in Asia. Methods: Our centre practises careful selection for HCC patients using the University of California, San Francisco (UCSF) criteria, supplemented by alpha-fetoprotein level and the model for end-stage liver disease score. Slight flexibility is offered to enthusiastic donors and recipients in LDLT while balancing the risks and benefits. We pioneered in using the extended right lobe graft and the novel hepatic venoplasty technique, which lessen the risk of hyperperfusion and small-for-size syndrome with improved overall recipient survival. Data were collected prospectively and presented as the mean values and ranges, or the number of patients in proportion of total patient population. Results: Of our patients, 74.9% met the UCSF criteria, and 64.5% met the Milan criteria. A 5-year overall and disease-free survival rate of 78.9% and 76.3% were achieved. Conclusion: LDLT is an ideal treatment for HCC in Hong Kong with regard to the critical organ shortage and high demand for transplantation. The current surgical techniques and post-transplant surveillance contribute to the positive outcome.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67653549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Sonography in surveillance for HCC in NAFLD patients 超声在NAFLD患者HCC监测中的应用

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2022.42

P. Radu, J. Dufour

引用次数: 0

Hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in sub-Saharan Africa: no room for complacency 撒哈拉以南非洲的乙型肝炎病毒(HBV)和肝细胞癌(HCC):不容自满

Hepatoma Research Pub Date : 2022-01-01 DOI: 10.20517/2394-5079.2022.11

P. Matthews, A. Kramvis

引用次数: 1